Navigation Links
Anti-HAV antibodies in beta-thalassemia
Date:4/30/2008

Thalassemic patients were found to present a higher prevalence of anti-HAV IgG antibodies than matched healthy subjects from the same geographic area. This finding is difficult to explain, but it may be attributed to the higher vulnerability of thalassemics to HAV infection and to passive transfer of anti-HAV antibodies by blood transfusion.

This study, performed by a team led by Associate Professor C Labropoulou-Karatza and Dr D Siagris, is described in a research article to be published on March 14, 2008, in the World Journal of Gastroenterology.

In Greece, the lack of Hepatitis A epidemics since the early 1980s and the improvement of socioeconomic and hygienic conditions over the last decade seem to have contributed to a decline in prevalence of anti-HAV antibodies. However, the authors observed that the majority of their beta-thalassemia patients were anti-HAV-IgG-positive.

In the view of the authors, the findings of this study are in contradiction with those of previous studies which showed a lower prevalence of anti-HAV antibodies in thalassemic patients.

In order to further reduce the incidence of liver infections in multitransfused thalassemic patients, the authors recommend active immunization for HAV in that population.

In the view of the reviewers, the strength of this study is surely due to the dimension of the population and the long history of the patients (10 years).

Further research, including testing the prevalence of anti-HAV antibodies in family members of thalassemia patients and in the frozen aliquots of donors plasma, would confirm these findings.


'/>"/>

Contact: Jing Zhu
wjg@wjgnet.com
0086-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Page: 1

Related medicine news :

1. Scripps Research scientists shed new light on how antibodies fight HIV
2. Micromets BiTE(R) Antibodies Reveal Unique Mode of Action
3. Prenatal exposure to maternal antibodies linked to autistic behaviors in offspring
4. Autoantibodies and neuropsychiatric events in lupus
5. Vegan diet promotes atheroprotective antibodies in patients with rheumatoid arthritis
6. Gene variant linked to moderated symptoms of beta-thalassemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... The American Board ... become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon ... beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice ... of cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... for their devotion to personalized service, SMP Pharmacy Solutions announces ... the South Florida Business Journal,s 50 Fastest-Growing Companies, and listed ... national specialty pharmacy has found its niche.  To that end, ... honored by SFBJ as the 2017 Power Leader in Health ... his award in October, Bardisa said of the three achievements, ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology: